Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Russell Davis

Podiatrist Greenbrae, CA Doctor of Podiatric Medicine

NPI 1376644799 CMS profile 244411

1000 S Eliseo Dr, Ste 102, Greenbrae, CA 94904

Open in the dashboard

General payments

$36,759

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Russell Davis of Greenbrae, CA is reported in the CMS Open Payments database as having received $36,759 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2023 General $29 1
2021 General $37 1
2020 General $36,405 4
2019 General $264 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Davis
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Russell Davis were reported at $24. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Russell Davis Podiatrist median Middle half National median
2019 $264 $196 $72–$601 $163
2020 $36,405 $118 $38–$335 $114
2021 $37 $169 $57–$573 $132
2022 $0 $220 $74–$782 $149
2023 $29 $208 $71–$635 $160
2024 $0 $237 $87–$681 $164
2025 $24 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $36,325 1 payment
  2. Wright Medical Technology, Inc. $191 7 payments
  3. Osiris Therapeutics Inc. $73 4 payments
  4. Integra LifeSciences Corporation $49 2 payments
  5. Zimmer Biomet Holdings, Inc. $37 1 payment
  6. DePuy Synthes Sales Inc. $31 1 payment
  7. Stryker Corporation $29 1 payment
  8. Abbott Laboratories $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $36,325 1 payment
  2. Food and Beverage $434 17 payments
Products named General payments · program years 2019–2025
  1. GRAFIX $36,398 5 payments
  2. GRAFIX PL $36,325 1 payment
  3. ORTHOLOC $136 2 payments
  4. Stravix $73 4 payments
  5. GrafixPL $73 4 payments
  6. AMNIOEXCEL $49 2 payments
  7. IDRT $49 2 payments
  8. PRIMATRIX $49 2 payments
  9. OMNIGRAFT $49 2 payments
  10. TCC-EZ $49 2 payments
  11. Other $208 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

338

Median for Podiatry: 160

Drug cost

$9,197

Median for Podiatry: $2,368

Branded share of claims

10.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Febuxostat Generic 28 $2,234
Clotrimazole Generic 88 $1,864
Colchicine Generic 38 $1,712
Lidocaine Generic 11 $1,147
Gabapentin Generic 59 $1,047
Allopurinol Generic 30 $367
Terbinafine Hcl Generic 26 $282
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $214
Probenecid-Colchicine Probenecid/Colchicine Brand 11 $179
Cephalexin Generic 12 $80

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$419,997

Of which drugs: $147

Medicare patients

824

Average age 77

Services billed

6,613

442 women, 382 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 49%
Diabetes 25%
Chronic kidney disease 25%
Ischemic heart disease 24%
Osteoporosis 21%
Atrial fibrillation 20%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 16 28 $147

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record